0001437749-13-013028.txt : 20131015 0001437749-13-013028.hdr.sgml : 20131014 20131015063227 ACCESSION NUMBER: 0001437749-13-013028 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20131015 DATE AS OF CHANGE: 20131015 EFFECTIVENESS DATE: 20131015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: K-V Pharmaceutical Co CENTRAL INDEX KEY: 0000057055 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430618919 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-06439 FILM NUMBER: 131149135 BUSINESS ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 BUSINESS PHONE: 3146456600 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: KV PHARMACEUTICAL CO /DE/ DATE OF NAME CHANGE: 19920703 15-12G 1 kva20131011_1512g.htm FORM 15-12G kva20131011_1512g.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION
12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

 

Commission File Number              001-09601                                     

 

K-V PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

 

16640 Chesterfield Grove Rd., Suite 200

Chesterfield, MO 63005

(314) 645-6600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Class A Common Stock, par value $0.01 per share1

Class B Common Stock, par value $0.01 per share1

7% Cumulative Convertible Preferred, par value $0.01 per share1

(Title of each class of securities covered by this Form)

 

12% Senior Secured Notes due 20151

2.5% Contingent Convertible Subordinated Notes due 20331

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

 Rule 12g-4(a)(1)

 ☒

 Rule 12g-4(a)(2)

 ☐

 Rule 12h-3(b)(1)(i)

 ☐

 Rule 12h-3(b)(1)(ii)

 ☐

 Rule 15d-6

 ☐

   

Approximate number of holders of record as of the certification or notice date:                         0                                                

 

Pursuant to the requirements of the Securities Exchange Act of 1934 K-V Pharmaceutical Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

By:

/s/ Gregory J. Divis

 

Gregory J. Divis, President and Chief Executive

Officer

 

Date: October 15, 2013

 

 

 

 

 

 

1 As more fully described in the Current Report on Form 8-K filed by K-V Pharmaceutical Company on September 23, 2013, these securities were cancelled in accordance with the Sixth Amended Joint Chapter 11 Plan of Reorganization of K-V Pharmaceutical Company and certain of its wholly-owned domestic subsidiaries (the “Plan”), effective September 16, 2013. In accordance with the Plan, the reorganized K-V Pharmaceutical Company issued certain shares of a new class of common stock, par value $0.01 per share (“New Common Stock”) to a limited number of institutional investors in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended. If, and to the extent, the New Common Stock is deemed to succeed to the Section 12 registration of the securities covered by this Form, this Form shall be deemed to terminate any such registration under Rule 12g-4(a)(1).